Medmira Stock Fundamentals
| MMIRF Stock | USD 0.06 0.00 0.00% |
MedMira fundamentals help investors to digest information that contributes to MedMira's financial success or failures. It also enables traders to predict the movement of MedMira Pink Sheet. The fundamental analysis module provides a way to measure MedMira's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to MedMira pink sheet.
MedMira |
MedMira Company Profit Margin Analysis
MedMira's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current MedMira Profit Margin | (2.27) % |
Most of MedMira's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, MedMira is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, MedMira has a Profit Margin of -2.2682%. This is 79.77% lower than that of the Health Care Equipment & Supplies sector and 90.15% lower than that of the Health Care industry. The profit margin for all United States stocks is 78.6% higher than that of the company.
MedMira Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining MedMira's current stock value. Our valuation model uses many indicators to compare MedMira value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across MedMira competition to find correlations between indicators driving MedMira's intrinsic value. More Info.MedMira is regarded second in return on asset category among its peers. It is considered to be number one stock in profit margin category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the MedMira's earnings, one of the primary drivers of an investment's value.Did you try this?
Run ETF Categories Now
ETF CategoriesList of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
| All Next | Launch Module |
MedMira Fundamentals
| Return On Asset | -0.23 | |||
| Profit Margin | (2.27) % | |||
| Operating Margin | (1.79) % | |||
| Current Valuation | 36.69 M | |||
| Shares Outstanding | 697.45 M | |||
| Shares Owned By Insiders | 70.39 % | |||
| Price To Earning | (3.72) X | |||
| Price To Sales | 36.63 X | |||
| Revenue | 952.13 K | |||
| Gross Profit | (512.51 K) | |||
| EBITDA | (1.07 M) | |||
| Net Income | (1.83 M) | |||
| Cash And Equivalents | 396.14 K | |||
| Total Debt | 40 K | |||
| Current Ratio | 0.14 X | |||
| Book Value Per Share | (0.02) X | |||
| Cash Flow From Operations | (1.88 M) | |||
| Earnings Per Share | (0) X | |||
| Number Of Employees | 15 | |||
| Beta | 10.61 | |||
| Market Capitalization | 77.78 M | |||
| Total Asset | 3.83 M | |||
| Net Asset | 3.83 M |
About MedMira Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze MedMira's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MedMira using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MedMira based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Latin America, the Caribbean, Europe, the Asia Pacific, and internationally. The company was founded in 1993 and is headquartered in Halifax, Canada. Medmira operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Currently Active Assets on Macroaxis
Other Information on Investing in MedMira Pink Sheet
MedMira financial ratios help investors to determine whether MedMira Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in MedMira with respect to the benefits of owning MedMira security.